Novocure flying on lung cancer trial data

Drug development company Novocure (Nasdaq: NVCR) today announced a positive update for its Phase 3 pivotal LUNAR lung cancer trial. The company said an Independent Data Monitoring Committee (DMC) informed it that the pre-set interim analysis of the LUNAR trial would be speeded up due to the length of entitlement and the number of events observed, and that the trial should continue without evidence of increased systemic toxicity. RELATED ARTICLES “One day every cancer patient will use our product” Oncology Co Novocure raised $ 150 million in Novocure bonds that today opened 48% higher on the Nasdaq at $ 195, giving a market cap of $ 20.034 billion. Before today, Novocure’s share price has increased by 92% over the past year, and by 440% in the past three years. The primary endpoint of a LUNAR trial is overall survival when patients are treated with TTFields plus an immune checkpoint inhibitor or docetaxel versus immune checkpoint inhibitors or docetaxel alone. The final analysis will also include an analysis of the overall survival in the immuno-checkpoint inhibitor group and docetaxel treatment subgroups. Novocure CEO Asaf Danziger said, “The completion of the interim LUNAR analysis is an important milestone for Novocure. We are grateful to DMC members for their diligence, guidance and support, and look forward to working closely with the FDA on modifications to DMC’s recommendations. Awaiting regulatory approval. , The recommended protocol modifications can accelerate the completion of the trial for more than a year. We look forward to sharing the final data from the LUNAR trial as quickly as possible. “NovoCure is essentially a completely new approach to cancer treatment, developed by Professor Yuram Balti, who is now 82 years old.” General, Professor Emeritus of Physiology and Biophysics at Technion-Israel Institute of Technology. It consists of electric fields directed at growth from several directions that disrupt the growth of cancer cells without harming other areas. Treatment is similar to radiation, but without the damage the radiation does to tissues on the way to growth. Now headquartered and registered in the United States, Novocure has 200 employees in Israel. Posted by Globes, Israel business news – en.globes.co.il – on April 13, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021